Skip to main content
SpringerLink
Log in

Future of COX2 inhibitors

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: 2004 Worldwide sales of arthritis drugs by class.
Figure 2: Global sales of prescription and over-the-counter COX inhibitors.
Figure 3: Prescription volumes of selective COX2 inhibitors from August 2004 to January 2005.

References

  1. FitzGerald, G. COX2 and beyond: Approaches to prostaglandin inhibition in human disease. Nature Rev. Drug Discov. 2, 879–890 (2003).

    Article  CAS  Google Scholar 

  2. Drazen, J. M. COX-2 inhibitors — a lesson in unexpected problems. N. Engl. J. Med. 352, 1131–1132 (2005).

    Article  CAS  Google Scholar 

  3. Psaty, B. M. et al. Cox-2 inhibitors — lessons in drug safety. N. Engl. J. Med. 352, 1133–1135 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ph.D., is a Vice President at MEDACorp, 1 Federal Street, Boston, 02110, Massachusetts, USA

    Irena Melnikova

Authors
  1. Irena Melnikova
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This article was written prior to the author's affiliation with MEDACorp.

Related links

Related links

FURTHER INFORMATION

FDA Memorandum

Rights and permissions

Reprints and permissions

About this article

Cite this article

Melnikova, I. Future of COX2 inhibitors. Nat Rev Drug Discov 4, 453–454 (2005). https://doi.org/10.1038/nrd1755

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1755

  • Springer Nature Limited

This article is cited by

Search

Navigation